Accession Number : ADA332970

Title :   Automated Rescreening of Pap Smears.

Descriptive Note : Final rept. 1 Dec 94-31 Dec 95,

Corporate Author : ARMED FORCES INST OF PATHOLOGY WASHINGTON DC

Personal Author(s) : O'Leary, Timothy J.

PDF Url : ADA332970

Report Date : JAN 1996

Pagination or Media Count : 20

Abstract : The objective of this study was to determine effectiveness and cost of Papnet-assisted rescreening in identifying cervical abnormalities not identified by manual Pap smear rescreening methods. Papnet-assisted rescreening was performed on using 5478 Pap smears previously identified as "within normal limits" or "benign changes" on both initial screening and random rescreening. Cases in which a diagnostic change was considered were reviewed by a panel of three cytotechnologists and three pathologists to obtain a consensus diagnosis. Follow-up was attempted on all patients for whom this panel believed a diagnosis of "atypical squamous cells of undetermined significance," (ASCUS) "atypical glandular cells of undetermined significance," (AGUS) or "squamous intraepithelial neoplasia" was warranted. Papnet-assisted examination identified 5 cases of ASCUS and 1 case of AGUS which had not been previously diagnosed; no additional squamous intraepithelial lesions were identified in these smears; the patient with a diagnosis of AGUS on the smear was diagnosed as having a low-grade squamous intraepithelial lesion on follow-up smear.A cost of $8564-34084 (depending on the Papnet charge) for each additional ASCUS/AGUS diagnosis, and a cost of $25691 - 104410 is expected for each case of low grade SIL identified by Papnet-assisted rescreening and not by traditional manual rescreening.

Descriptors :   *CELLS, *FEMALES, *ABNORMALITIES, *GYNECOLOGY, MILITARY PERSONNEL, MILITARY FACILITIES, HEALTH, COSTS, MILITARY MEDICINE, DIAGNOSIS(GENERAL), PATIENTS, WOMEN, LESIONS, CANCER, MORBIDITY, PATHOLOGISTS.

Subject Categories : Anatomy and Physiology
      Medicine and Medical Research

Distribution Statement : APPROVED FOR PUBLIC RELEASE